Nusayba Bagegni

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Triple Negative Breast Neoplasms 78%
3. palbociclib 69%
4. Circulating Tumor DNA 62%
5. pembrolizumab 43%
6. human MMP12 protein 43%
7. Radiation induced brachial plexopathy 43%
8. N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 37%
9. thymidine kinase 1 36%
10. Matrix Metalloproteinase 12 34%
11. Cyclin-Dependent Kinase 6 33%
12. Mutation 32%
13. Cyclin-Dependent Kinase 4 30%
14. Letrozole 30%
15. Lobular Carcinoma 29%
16. Adjuvant Chemotherapy 26%
17. Trastuzumab 25%
18. Drug Therapy 25%
19. Neoadjuvant Therapy 25%
20. Carboplatin 24%
21. Docetaxel 24%
22. Neoplasms 23%
23. Histology 19%
24. Vascular Endothelial Growth Factor A 18%
25. Diarrhea 18%
26. Clone Cells 17%
27. Clinical Trials 17%
28. Radiotherapy 15%
29. Databases 13%
30. Genes 13%
31. Catalytic Domain 13%
32. Nivolumab 12%
33. Therapeutics 12%
34. Whole Exome Sequencing 12%
35. RNA Sequence Analysis 12%
36. Ductal Carcinoma 11%
37. Residual Neoplasm 10%
38. Matrix Metalloproteinases 10%
39. Serum 9%
40. DNA Damage 9%
41. Leukopenia 9%
42. Antidiarrheals 9%
43. Chemical Databases 8%
44. Population 8%
45. Odds Ratio 8%
46. Immunotherapy 7%
47. Medical Futility 7%
48. Down-Regulation 7%
49. Confidence Intervals 7%
50. Mechanistic Target of Rapamycin Complex 1 6%